| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |



§¶
From the Laboratoire de Biopathologie Nerveuse et
Musculaire,*
IBDMFaculté de Médecine Timone;
the Service d'Hématologie,§
Hôpital de
la Conception; the Centre d'Immunologie,
UMR
INSERM-CNRS 145; the Laboratoire de Génétique et de
Physiologie du Développement,
UMR 6545
CNRS, IBDM, Parc Scientifique de Luminy; and the Institut Universitaire
de France,¶
Marseilles, France
PEN5 is a sulfated polylactosamine carbohydrate epitope first described in a subpopulation of mature natural killer cells. Here we report that it is also expressed in a developmentally regulated fashion in human and rat central nervous systems and that its protein carrier is P-selectin glycoprotein ligand-1 (PSGL-1), a ligand for selectins. In rat neural primary cultures, PEN5 is transiently and selectively expressed by oligodendrocyte precursor cells and marks the transition from proliferative to postmitotic stages. In concordance, in human central nervous system tumors, PEN5 is observed in a subset of oligodendrogliomas and in all pilocytic astrocytomas, a class of tumor of uncertain histogenesis. These data suggest that PEN5-PSGL-1 plays a role in the differentiation of oligodendrocytes and that pilocytic astrocytomas are likely to result from a dysregulation occurring in oligodendrocyte precursor cells at the crucial stage of exit from the cell cycle.
This article has been cited by other articles:
![]() |
A. Tchoghandjian, C. Fernandez, C. Colin, I. El Ayachi, B. Voutsinos-Porche, F. Fina, D. Scavarda, M.-D. Piercecchi-Marti, D. Intagliata, L. Ouafik, et al. Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature Brain, June 1, 2009; 132(6): 1523 - 1535. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yokoo, S. Nobusawa, H. Takebayashi, K. Ikenaka, K. Isoda, M. Kamiya, A. Sasaki, J. Hirato, and Y. Nakazato Anti-Human Olig2 Antibody as a Useful Immunohistochemical Marker of Normal Oligodendrocytes and Gliomas Am. J. Pathol., May 1, 2004; 164(5): 1717 - 1725. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tada, M. Kochi, H. Saya, J.-i. Kuratsu, S. Shiraishi, T. Kamiryo, N. Shinojima, and Y. Ushio Preliminary observations on genetic alterations in pilocytic astrocytomas associated with neurofibromatosis 1 Neuro-oncol, October 1, 2003; 5(4): 228 - 234. [Abstract] [PDF] |
||||
![]() |
A. Leppanen, L. Penttila, O. Renkonen, R. P. McEver, and R. D. Cummings Glycosulfopeptides with O-Glycans Containing Sialylated and Polyfucosylated Polylactosamine Bind with Low Affinity to P-selectin J. Biol. Chem., October 11, 2002; 277(42): 39749 - 39759. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Gutmann Review Article : Neurofibromin in the Brain J Child Neurol, August 1, 2002; 17(8): 592 - 601. [Abstract] [PDF] |
||||
![]() |
M. L. Bajenaru, Y. Zhu, N. M. Hedrick, J. Donahoe, L. F. Parada, and D. H. Gutmann Astrocyte-Specific Inactivation of the Neurofibromatosis 1 Gene (NF1) Is Insufficient for Astrocytoma Formation Mol. Cell. Biol., July 15, 2002; 22(14): 5100 - 5113. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ong, M. Suzuki, F. Belot, J.-C. Yeh, I. Franceschini, K. Angata, O. Hindsgaul, and M. Fukuda Biosynthesis of HNK-1 Glycans on O-Linked Oligosaccharides Attached to the Neural Cell Adhesion Molecule (NCAM). THE REQUIREMENT FOR CORE 2 beta 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE AND THE MUSCLE-SPECIFIC DOMAIN IN NCAM J. Biol. Chem., May 10, 2002; 277(20): 18182 - 18190. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Gutmann, N. M. Hedrick, J. Li, R. Nagarajan, A. Perry, and M. A. Watson Comparative Gene Expression Profile Analysis of Neurofibromatosis 1-associated and Sporadic Pilocytic Astrocytomas Cancer Res., April 1, 2002; 62(7): 2085 - 2091. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, A. Perry, C. D. James, and D. H. Gutmann Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas Neurology, April 10, 2001; 56(7): 885 - 890. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |